Sec Form 4 Filing - Schroeder Theodore R @ Nabriva Therapeutics plc - 2019-07-25

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Schroeder Theodore R 2. Issuer Name and Ticker or Trading Symbol Nabriva Therapeutics plc [ NBRV] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) 1000 CONTINENTAL DRIVE, SUITE 600 3. Date of Earliest Transaction (MM/DD/YY) 07/25/2019 (Street) KING OF PRUSSIA, PA19406 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 07/25/2019 A 6,748 A 67,489 I Schroeder Living Trust Ordinary Shares 5,786 ( 2 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Schroeder Theodore R 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA, PA19406 X Chief Executive Officer Signatures /s/ Robert Crotty, by power of attorney 07/25/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )In connection with the acquisition (the "Acquisition") of Zavante Therapeutics, Inc. ("Zavante") by Nabriva Therapeutics plc (the "Issuer") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated July 23, 2018, in exchange for the reporting person's security holdings in Zavante, such reporting person became entitled to receive 60,741 ordinary shares of the Issuer and up to an additional 6,748 ordinary shares (the "Holdback Shares"), which were held back by the Issuer as security for the satisfaction of indemnification and other obligations of the former Zavante security holders under the Merger Agreement. Pursuant to the terms of the Merger Agreement, upon the occurrence of the first business day following the first anniversary of the closing date of the Acquisition, the Holdback Shares were issued to the reporting person. ( 2 )Represents ordinary shares acquired by the reporting person under the Issuer's 2018 Employee Share Purchase Plan on April 30, 2019.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.